Literature DB >> 12356386

Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).

Leanne Streja1, Chris J Packard, James Shepherd, Stuart Cobbe, Ian Ford.   

Abstract

Statins are regarded as efficacious in general but there is a wide variation in individual response. We sought demographic and lifestyle factors that influenced the response to pravastatin 40 mg/day in moderately hypercholesterolemic men in the West Of Scotland Coronary Prevention Study (WOSCOPS). Changes in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol after 6 months of treatment were examined in 1,604 highly compliant subjects. LDL cholesterol decreased by a mean of 30.4%. The magnitude of the change was influenced, albeit to a small extent, by baseline plasma triglyceride levels and alcohol intake and age; subjects with low plasma triglyceride levels, older subjects, and subjects with low alcohol intake had the greatest reductions. The mean response in HDL cholesterol in the group was an 8.3% increase (0.09 mmol/L). The percent increase in HDL cholesterol was affected by baseline HDL level, plasma triglyceride levels, decrease in plasma triglyceride levels during the administration of pravastatin, and body mass index. The absolute increase in HDL cholesterol was influenced by the decrease in plasma triglyceride levels, body mass index, and alcohol intake. All of these associations were weak (r <0.2) although highly significant. In conclusion, plasma lipid phenotype, obesity, and alcohol consumption appear to influence the response of LDL and HDL cholesterol to statin treatment. The absolute increment in HDL cholesterol is relatively constant across a range of baseline values, hence the percent change is largely a function of the starting value.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356386     DOI: 10.1016/s0002-9149(02)02599-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.

Authors:  San-Chiang Wu; Jeng-Chuan Shiang; Shoa-Lin Lin; Te-Lang Wu; Wei-Chun Huang; Kuan-Rau Chiou; Chun-Peng Liu
Journal:  Heart Vessels       Date:  2005-09       Impact factor: 2.037

3.  Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.

Authors:  Ronald B Goldberg; John R Guyton; Theodore Mazzone; Ruth S Weinstock; Adam B Polis; Diane Tipping; Joanne E Tomassini; Andrew M Tershakovec
Journal:  Diabetes Care       Date:  2010-02-11       Impact factor: 19.112

4.  Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women.

Authors:  Heiner K Berthold; Susanne Unverdorben; Armin Zittermann; Ralf Degenhardt; Bernhard Baumeister; Martin Unverdorben; Wilhelm Krone; Hans Vetter; Ioanna Gouni-Berthold
Journal:  Osteoporos Int       Date:  2004-02-14       Impact factor: 4.507

5.  Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.

Authors:  Heli Halava; Arja Helin-Salmivaara; Jouni Junnila; Risto Huupponen
Journal:  Eur J Clin Pharmacol       Date:  2009-05-27       Impact factor: 2.953

6.  Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.

Authors:  Marisa Wong Medina; Feng Gao; Weiming Ruan; Jerome I Rotter; Ronald M Krauss
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

Review 7.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

8.  Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells.

Authors:  Makoto Seo; Ikuo Inoue; Masaaki Ikeda; Takanari Nakano; Seiichiro Takahashi; Shigehiro Katayama; Tsugikazu Komoda
Journal:  PPAR Res       Date:  2008-12-24       Impact factor: 4.964

Review 9.  Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

Authors:  Fergus McTaggart; Peter Jones
Journal:  Cardiovasc Drugs Ther       Date:  2008-06-14       Impact factor: 3.727

Review 10.  Management of Measurable Variable Cardiovascular Disease' Risk Factors.

Authors:  Sonja Francula-Zaninovic; Iskra A Nola
Journal:  Curr Cardiol Rev       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.